Can-Fite BioPharma Ltd.
New York Stock Exchange AmericanTotal Valuation
Can-Fite BioPharma Ltd. carries a market capitalization of 2.11M, placing it among publicly traded companies globally. Its enterprise value stands at -236,968.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.11M |
| Enterprise Value | -236,968.00 |
Share Statistics
Can-Fite BioPharma Ltd. currently has 453,279.00 shares outstanding.
| Shares Outstanding | 453,279.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 11.64, and the price-to-book ratio stands at -0.05.
| PE Ratio | N/A |
| PS Ratio | 11.64 |
| PB Ratio | -0.05 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Can-Fite BioPharma Ltd. maintains a current ratio of 4.90, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.90 |
| Quick Ratio | 4.42 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -79.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Can-Fite BioPharma Ltd.'s stock has declined approximately -80.77647% over the past 52 weeks. The 50-day moving average sits at 3.20, while the 200-day moving average is 5.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -80.77647% |
| 50-Day Moving Average | 3.20 |
| 200-Day Moving Average | 5.48 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Can-Fite BioPharma Ltd. generated 743,000.00 in revenue and converted that into -7.63M in net income, yielding earnings per share of -38.85. EBITDA reached -8.19M, while operating income came in at -8.19M.
| Revenue | 743,000.00 |
| Gross Profit | N/A |
| Operating Income | -8.19M |
| Pretax Income | -7.63M |
| Net Income | -7.63M |
| EBITDA | -8.19M |
| EBIT | -8.19M |
| Earnings Per Share (EPS) | -38.85 |
Balance Sheet
Can-Fite BioPharma Ltd. holds 8.92M in cash and equivalents against 40,000.00 in total debt, resulting in a net debt position of -4.28M. Total book value stands at -158.48M, with working capital of 7.89M providing operational flexibility.
| Cash & Cash Equivalents | 8.92M |
| Total Debt | 40,000.00 |
| Net Debt | -4.28M |
| Equity (Book Value) | -158.48M |
| Book Value Per Share | -806.61 |
| Working Capital | 7.89M |
Margins
Can-Fite BioPharma Ltd. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,102.96 and net profit margin of -1,027.46 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,102.96 |
| Pretax Margin | -1,027.46 |
| Profit Margin | -1,027.46 |
| EBITDA Margin | -1,102.96 |
Stock Splits
Can-Fite BioPharma Ltd.'s most recent stock split took place on January 5, 2026 with a 20:1 split ratio.
| Last Split Date | 1/5/2026 |
| Split Ratio | 20:1 |
Scores
Can-Fite BioPharma Ltd. posts an Altman Z-Score of -22.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -22.51 |